The most reliable predictor of why a routine visit turns into a surprisingly large bill is not the medicine delivered but the ownership of the place delivering it; when hospitals, health plans, and pharmacy middlemen buy the doctors’ offices and pharmacies upstream and downstream, care is quietly steered to higher-priced settings and affiliated channels where extra fees and margins are captured.
The Short Version
- Hospital ownership of physician practices enables facility fees and site-based billing that inflate charges for identical services.
- Vertical physician–hospital integration is consistently associated with higher commercial and Medicare prices for physician services.
- PBM and pharmacy ownership links enable prescription steering to affiliated pharmacies; benefits to patients are contested and often offset by opaque pricing.
- Policy proposals largely converge on site-neutral payment, guardrails on steering, and targeted transparency rather than blanket bans on integration.
How ownership changes the bill: the mechanism, not the marketing
Vertical integration in health care is not just a governance chart; it is a routing algorithm for revenue. When a hospital acquires a physician practice, the same clinician visit can be billed as “hospital outpatient” rather than “physician office,” layering a facility fee on top of the professional fee. Medicare’s own advisory commission has been explicit: acquisitions enable exploitation of site-based payment differentials, allowing hospitals to add facility charges in formerly independent offices, raising program and beneficiary costs without changing the underlying service mix.
Prices also rise through bargaining leverage. Once physicians are absorbed into a hospital system, the combined entity negotiates as one, often commanding higher commercial rates for physician services. MedPAC’s earlier synthesis is unambiguous: vertical physician–hospital consolidation increases both commercial and Medicare prices paid for physician services. Those higher prices are not a function of better technology at the bedside; they are a function of billing category and market power.
Steering is the quiet profit engine
Integration works by shifting where and through whom a given service flows. In outpatient care, that can mean moving imaging, infusions, or minor procedures into hospital outpatient departments with richer reimbursement. In pharmacy, it means controlling the pathway from prescription to dispense. The Federal Trade Commission’s PBM inquiry, summarized in expert testimony to Congress, argues that vertically integrated PBMs can steer specialty drugs to their affiliated pharmacies and pay those affiliates higher reimbursements than independents receive—an internal routing choice that advantages the corporate family, not necessarily the patient.
These steering choices compound. A hospital-owned oncology clinic, for example, can both capture a facility fee on the visit and funnel infused or specialty drugs through an affiliated specialty pharmacy, stacking margins across the chain. For patients in high-deductible or coinsurance designs, those setting and channel choices turn into higher out-of-pocket exposure before any clinical difference is involved.
What the best evidence says: higher prices are the base case
Across settings and methods, the preponderance of empirical work finds that vertical physician–hospital ties raise prices. MedPAC’s 2017 analysis attributed higher physician service prices to vertical consolidation, and its subsequent reports have tied payment differentials to specific billing pathways exploited post-acquisition. Outside Medicare, economic syntheses cited by policy forums peg price increases from vertical hospital–physician consolidation in the mid-teens to low-thirties percent range, depending on market structure and contracting scope.
Not every form of integration raises every price; there are nuanced results in post-acute care and condition-specific bundles. But as a base rate, when common services migrate from independent offices to hospital outpatient departments, total spending climbs. Medicare’s own discussion of post-acute placement illustrates the mechanical logic: large price differences among settings give health plans a financial incentive to choose lower-cost sites; providers integrated with higher-paid settings naturally push the other way. Where billing categories diverge, integration arbitrages the gap.
The credible countercase: drug benefits inside insurer-PBM stacks
There is one notable, bounded counterexample: when a health insurer owns a PBM, incentive alignment can lower the prices the plan pays for drugs. The Congressional Budget Office, after reviewing claims and contracting structures, concluded that insurer-PBM vertical integration tends to reduce plan drug spending for enrollees in those vertically integrated plans, by coordinating formulary, rebate, and network decisions under one balance sheet.
Two cautions are essential. First, the CBO’s finding is specific to drug prices borne by the plan; it does not assert that patient out-of-pocket costs fall in lockstep, which can diverge because copays and coinsurance often track list prices rather than net-of-rebate costs. Second, the same alignment that lowers plan costs can intensify steering to affiliated pharmacies—a dynamic the FTC has flagged—raising questions about access and the distribution of margin across the supply chain even when the plan’s net spend declines. Both statements can be true: the plan saves; the corporate family gains scope; the patient’s cost-sharing experience is mixed.
Why this keeps happening: incentives embedded in payment policy
Vertical integration is a rational response to price relativities baked into fee schedules and contracts. When identical services command higher reimbursement in one setting than another, ownership gives organizations a compliant way to reclassify the setting. No amount of mission language will neutralize that math. As long as a hospital can legitimately add a facility fee to a blood draw, an echocardiogram, or a routine visit in an acquired clinic, acquisitions will continue to pencil out—because the spread is policy-created, not technology-justified.
The same is true in pharmacy: if rebate and network rules reward channel control and volume commitments, common ownership between plan, PBM, and specialty pharmacy will push prescriptions toward insiders. The pattern is not mysterious; it is the predictable byproduct of reimbursement design and contracting latitude.
Quality and coordination: promised, uneven, and rarely priced in
Proponents of integration rightly argue that single-entity control can coordinate care, streamline prior authorizations, and reduce duplicative testing. Some studies in narrow programs—bundled payments or comprehensive local systems—show modest episode savings or shorter lengths of stay without clear harm to outcomes. But across general outpatient and physician services, systematic reviews report ambiguous quality effects alongside higher spending, suggesting coordination gains are not consistently translated into lower prices for payers or patients under current payment rules. In plain terms: the clinical logic for integration does not guarantee a financial dividend to patients when price differentials and market power dominate.
What would curb the bill inflation without banning integration
Three policy levers recur across credible analyses. First, site-neutral payment for common outpatient services would deflate the facility-fee arbitrage that makes acquisitions self-financing on paper; even partial site neutrality aimed at evaluation and management visits and routine imaging would meaningfully narrow spreads. Second, guardrails on steering—disclosure, fair-reimbursement standards for affiliated versus nonaffiliated pharmacies, and limits on anti-competitive contracting—can preserve patient access while allowing plans to pursue genuine coordination. Third, targeted transparency focused on the contract units that move money (place of service, add-on fees, spread-pricing constructs) can help purchasers—especially self-funded employers—counteract steering with benefit design and network selection.
None of these require outlawing vertical ownership. They require neutralizing the payment differentials and opaque channel rents that make steering profitable in the first place. When the spread disappears, the acquisition case must rest on real operating efficiencies and quality—claims that can then be tested in prices, not just press releases.
What it means for patients and purchasers
For patients, the practical step is prosaic but powerful: ask where a service will be billed and at what place-of-service code before it is scheduled; shifting a routine test from a hospital outpatient department to an independent site can cut out-of-pocket costs dramatically in high-deductible designs. For employers and unions, steerage rights and place-of-service incentives in plan documents, coupled with centers-of-excellence and reference pricing, can reclaim volume from high-fee sites that add no clinical value. For policymakers, the durable fix is structural: align payment for like services across sites and require neutral network rules that keep affiliated and unaffiliated providers on comparable terms when quality is equal.
Sources:
aapm.org, medpac.gov, warren.senate.gov, congress.gov, sciencedirect.com, pharmacytimes.com
